Symptomatic and Sonographic Improvement of Immune Checkpoint Inhibitor Enterocolitis With Risankizumab
Lay Summary Immune checkpoint inhibitor-induced (CPI) enterocolitis is a frequent complication of cancer immunotherapy. This case details the treatment of CPI enterocolitis with risankizumab (anti-IL23) and the use of intestinal ultrasound (IUS) to noninvasively monitor treatment response. This report is clinically relevant given the frequency of CPI enterocolitis and the expanding applications of IUS.
Authors
- Rishika Chugh (ORCID: https://orcid.org/0000-0003-4175-7889)
- Rena Mei (ORCID: https://orcid.org/0000-0001-5436-1977)
- David Yoonsuk Oh (ORCID: https://orcid.org/0000-0002-3310-0994)
- Ernesto Pepe
- Michael G. Kattah (ORCID: https://orcid.org/0000-0002-6067-6585)
- Katy K. Tsai
Institutions
- University of California, San Francisco (US)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1093/ibd/izae259
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28